Anika Therapeutics (NASDAQ: ANIK) revenue
Anika Therapeutics reported revenue of $112.8m for fiscal 2025, 5.9% less than in fiscal 2024 ($119.9m). Since fiscal 2016 its revenue has grown by 9.1%, an average growth of 1.0% a year.
Anika Therapeutics's revenue has fallen for 2 years in a row, and its best year of the last 10 was fiscal 2021. The biggest drop was in fiscal 2022, −23.0%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $112.8m | −5.9% | −$11.1m | −9.8% |
| 2024 | $119.9m | −0.7% | −$5.1m | −4.3% |
| 2023 | $120.8m | +6.1% | $0.8m | 0.7% |
| 2022 | $113.8m | −23.0% | $3.7m | 3.2% |
| 2021 | $147.8m | +13.3% | $2.6m | 1.8% |
| 2020 | $130.5m | +13.8% | −$28.3m | −21.7% |
| 2019 | $114.6m | +8.6% | $34.2m | 29.9% |
| 2018 | $105.6m | −6.9% | $21.7m | 20.6% |
| 2017 | $113.4m | +9.7% | $45.7m | 40.3% |
| 2016 | $103.4m | — | $50.6m | 49.0% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Anika Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Anika Therapeutics ranks 279th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Anika Therapeutics, −5.9%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 277th | Agenus | $114.2m | 10.4% |
| 278th | Immunitybio | $113.3m | 668.3% |
| 279th | Anika Therapeutics | $112.8m | −5.9% |
| 280th | UroGen Pharma | $109.8m | 21.4% |
| 281st | Century Therapeutics | $109.2m | 1,556.8% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Anika Therapeutics
- How much revenue did Anika Therapeutics make in fiscal 2025?
- Anika Therapeutics reported revenue of $112.8m for fiscal 2025, compared with $119.9m in fiscal 2024.
- How much has the revenue of Anika Therapeutics grown?
- Between fiscal 2016 and fiscal 2025 it went from $103.4m to $112.8m: 9.1% more, an average growth of 1.0% a year.
- What was the best year for revenue at Anika Therapeutics?
- Of its last 10 fiscal years, fiscal 2021, with $147.8m.
- Where does Anika Therapeutics rank in its sector by revenue?
- It ranks 279th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Anika Therapeutics come from?
- From the annual report (Form 10-K) that Anika Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Anika Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Anika Therapeutics: the Anika Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.